Literature DB >> 21325387

Glucagon-like peptide-1 analogues for type 2 diabetes.

John P H Wilding1, Kevin Hardy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21325387     DOI： 10.1136/bmj.d410

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  3 in total

Review 1.  The management of patients with polycystic ovary syndrome.

Authors:  Channa N Jayasena; Stephen Franks
Journal:  Nat Rev Endocrinol       Date:  2014-07-15       Impact factor: 43.330

2.  Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study.

Authors:  Kohei Kaku; Hirotaka Watada; Yasuhiko Iwamoto; Kazunori Utsunomiya; Yasuo Terauchi; Kazuyuki Tobe; Yukio Tanizawa; Eiichi Araki; Masamichi Ueda; Hideki Suganami; Daisuke Watanabe
Journal:  Cardiovasc Diabetol       Date:  2014-03-28       Impact factor: 9.951

3.  Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: A meta-analysis.

Authors:  Xiaoling Cai; Liwei Ji; Yifei Chen; Wenjia Yang; Lingli Zhou; Xueyao Han; Simin Zhang; Linong Ji
Journal:  J Diabetes Investig       Date:  2017-03-23       Impact factor: 4.232
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.